About Syntis
Syntis is a company based in Boston (United States) founded in 2021 by Robert Langer, Rahul Dhanda, and Giovanni Traverso. Syntis has raised $65.88 million across 5 funding rounds from investors including NIH, Colorcon and W. R. Berkley. Syntis offers products and services including SYNT-101. Syntis operates in a competitive market with competitors including Fagron, Ignota Labs, RareStone Group, Revelation Pharma and Pharmedium, among others.
- Headquarter Boston, United States
- Founders Robert Langer, Rahul Dhanda, Giovanni Traverso
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Syntis Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.88 M (USD)
in 5 rounds
-
Latest Funding Round
$33 M (USD), Series A
Jul 01, 2025
-
Investors
NIH
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Syntis
Syntis offers a comprehensive portfolio of products and services, including SYNT-101.
Oral treatment for obesity that mimics gastric bypass effects.
Funding Insights of Syntis
Syntis has successfully raised a total of $65.88M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $33 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syntis
Syntis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Colorcon and W. R. Berkley.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage life sciences and tech focused VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Safar Partners is engaged in investing in technology startups.
|
Locked | Locked | Locked |
Investor details for Syntis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syntis
Investment portfolio details for Syntis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Syntis
Detailed financials for Syntis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syntis Comparisons
Peer comparison for Syntis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syntis
Syntis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fagron, Ignota Labs, RareStone Group, Revelation Pharma and Pharmedium, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug compounding services are provided by Fagron.
|
|
| Locked | Locked | Locked |
AI-driven toxicity prediction tools for early-stage drug discovery scientists
|
|
| Locked | Locked | Locked |
Provider of network and treatments to individuals and their families affected by rare diseases drugs
|
|
| Locked | Locked | Locked |
A network of compounding pharmacies is operated nationwide.
|
|
| Locked | Locked | Locked |
Drug compounding services are provided to healthcare facilities nationwide.
|
Detailed competitors of Syntis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syntis
Complete news archive for Syntis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syntis
Syntis was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Syntis is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Rahul Dhanda is the current CEO of Syntis. They have also founded this company.
Syntis is a funded company, having raised a total of $65.88M across 5 funding rounds to date.
Syntis was founded in 2021 in Boston, United States, by co-founders Robert Langer, Rahul Dhanda, and Giovanni Traverso. The company operates within the pharmaceutical sector, where customized drug compounding services are delivered. These services involve the preparation of tailored medications to meet specific patient requirements. Focus is placed on sterile compounding processes compliant with regulatory standards, supporting healthcare providers across the region.
Syntis's top competitors include Ignota Labs, Fagron and RareStone Group.
Syntis offers SYNT-101.
Syntis has 11 investors. Key investors include NIH, Colorcon, W. R. Berkley, Cerity Partners, and Mansueto Office.